Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2017-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial
effects when combined with paclitaxel in women with platinum resistant ovarian cancer.
Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone
chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).